Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Infectious Diseases

Open Access

Clinical utility of the GeneXpert assay for the diagnosis of Clostridium difficile infections

  • Dragoş Florea1, 2Email author,
  • Dan Oțelea1,
  • Alexandru Rafila1, 2,
  • Ioana Bădicuț1, 2,
  • Mona Popoiu1 and
  • Gabriel Adrian Popescu1, 2
BMC Infectious Diseases201414(Suppl 7):O34

https://doi.org/10.1186/1471-2334-14-S7-O34

Published: 15 October 2014

Background

Since 2011 a rapid increase of cases with Clostridium difficile infection (CDI) was observed in the National Institute for Infectious Diseases (NIID), the largest tertiary level infectious diseases hospital in Romania. The need of a fast and accurate diagnosis of CDI and the low sensitivity of the available rapid immunoassays supported the introduction of a molecular assay as a part of the CDI diagnostic strategy. The present study aimed to evaluate the clinical utility of the GeneXpert Clostridium difficile (Cepheid, Sunnyvale, CA) assay in the diagnosis of CDI cases in NIID.

Methods

Retrospective study of the CDI cases admitted or presented at NIID between January 2013 and August 2014. We used the medical records to analyze the demographic and medical data of each patient, the positivity rate and the time to result for the GeneXpert assay and for the standard solid medium anaerobic cultivation.

Results

A number of 1454 samples from 1289 patients were tested with GeneXpert in the last 19 months. The mean age in the studied group was 59 years (0-95 years) and the male:female ratio was 1:1.32. Approximately half (49.2%) of the samples tested with the molecular assay were positive for toxigenic C. difficile. A presumptive identification of C. difficile ribotype 027 was done in most (80.8%) of the positive samples. Due to its sample based format the molecular assay had a much shorter time to result than the standard culture tests (2.47 hours versus 3.86 days).

Conclusion

Sample based molecular assays are an important tool in the management of CDI, providing valuable information for timely treatment decisions and for appropriate institutional infection control procedures.

Authors’ Affiliations

(1)
National Institute for Infectious Diseases "Prof. Dr. Matei Balş"
(2)
Carol Davila University of Medicine and Pharmacy

Copyright

© Florea et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement